Phaseline

Targets › PFATP4

PFATP4: drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 2; Infectious disease; next expected readout Feb 2027.

Open in Phaseline: the race on PFATP4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
NovartisCipargamin (KAE609)
P-type ATPase inhibitor
PFATP4Phase 2Uncomplicated Plasmodium Falciparum MalariaFeb 2027

Conditions

Uncomplicated Plasmodium Falciparum Malaria (2)

Modalities

small molecule (1)

Companies

Novartis (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.